Subject matter experts will present the latest updates on treatments and reproduction techniques, in the context of fertility experts today symposium organized by MSD, held in Malaga on 10 and 11 May.

 "This symposium is an opportunity to bring together most professionals working in human reproduction to discuss current issues related to our specialty," said Dr. Buenaventura Coroleu, Head of Reproductive Medicine Dexeus University Institute and one of the speakers at the meeting. Among the novelties, Dr. Coroleu highlights "the analysis of the new options for preservation of fertility, both medical cause as the patient voluntary desire, as well as developments in diagnostic and therapeutic options for patients with poor response to Assisted reproductive cycle or ovarian stimulation treatments oocyte donors. "

As part of the symposium, Dr. Buenaventura Coroleu, Head of Reproductive Medicine Dexeus University Institute, explained that "evolution in assisted reproduction techniques in the last ten years has been very positive. Mainly by the simplicity of the treatment of ovulation stimulators, where stands for example the use of alpha coriflolitropina, which reduces the need punctures seven day to one week, a reduction in adverse effects such as ovarian hyperstimulation and multiple pregnancies. Finally, is the increase of efficiency, with a significant increase in pregnancy rates. "

Efficacy, safety profile and convenience considerations for choosing treatment

The Symposium also analyzed aspects to consider when choosing the right treatment for each patient. Dr. Coroleu notes that "the efficacy, safety profile and convenience are the most important keys to the choice of treatment. Of course, we must take into account the age of the patient, her Body Mass Index (BMI), hormone profile and ovarian reserve ". Whether the patient must be involved in the choice of treatment, Dr. Coroleu believes that "the most important is choosing the best technique and drugs for each patient. Considering this aspect, patients are concerned about the comfort of the treatment, and in these cases we have alternatives to conventional shots mean less patient. This is the case of alpha Corifollitropin. One treatment that has demonstrated efficacy and good safety profile for women who are going to be subjected to a cycle of in vitro fertilization ".

Corifollitropin alpha (ELONVA ®) is a subcutaneous injection for ovarian stimulation the patient is applied once a week1, achieving, with a single injection, the same efficiency as a daily injection of recombinant follitropin for seven days1, 2.
The couples come with misinformation to the first consultation

Dr. Buenaventura Coroleu noted the importance of the information given to the patient before starting any treatment: "More and more couples who come to see for reproductive problems more familiar with the different techniques. But, many times, we must clarify doubts arising from an excess of information is not always true. " Dr. Coroleu has pointed to the important work done by the scientific societies in this field "spend much of their efforts to disseminate scientifically correct".
About MSD

Today's MSD is a global healthcare leader working to contribute to global health. MSD is known as Merck & Co., Inc. in the U.S. and Canada. Through our medicines, vaccines, biologic therapies, and consumer products veterinarians we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information visit and follow us on Twitter, Facebook and YouTube.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Reform Act Private Securities Litigation United States (1995). These statements are based on current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. If underlying assumptions prove incorrect or risks and uncertainties materialize, actual results may differ from those discussed in the forward-looking statements.

The risks and uncertainties include, among others, general industry conditions and competition, general economic factors such as interest rate or currency exchange rate fluctuations, the impact of pharmaceutical industry regulation and legislation health care in the United States and internationally, the global trend towards restricting pharmaceutical expenditure, advances in technology and new products and patents attained by competitors; challenges inherent in new product development, including obtaining the approval of regulatory agencies, the ability of MSD to accurately predict future market conditions, difficulties and delays in the manufacturing process, the financial instability of international economies and sovereign risk, the dependence of the effectiveness of patents and other protections for innovative products from MSD, and the exposure to litigation (including those relating to patents) and / or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause actual results to differ materially from those described in the forward-looking statements may be found in Merck's Annual Report 2012 on Form 10-K, and other documents of the Company filed with the Commission Stock Exchange and Securities and Exchange (SEC) which are available on the website of the SEC (

    ELONVA datasheet
    Devroey P, Boostanfar R, Koper NP, Mannaerts BM, PC Ijzerman-Boon, Fauser BC. A double-blind, non-inferiority RCT Comparing alfa and recombinant FSH Corifollitropin During the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009, 24: 3063-3072.

Fotografía: See page for author [Public domain], <a href="">via Wikimedia Commons</a>